Onkologische Thoraxchirurgie während der COVID-19-Pandemie: eine Fallkontrollstudie zum Risiko für postoperative Komplikationen

 

 Buy Article Permissions and Reprints

Zusammenfassung

Hintergrund Die COVID-19-Pandemie hatte, neben der offensichtlichen Bedeutung als eigenständige Erkrankung, einen schwerwiegenden Einfluss auf alle Aspekte der medizinischen Versorgung. In der onkologischen Chirurgie mussten Operationen verschoben werden oder es kam zu verzögerten Diagnosen onkologischer Erkrankungen, was neben der Sorge um unzureichende Ressourcen auch in der Unsicherheit bezüglich der perioperativen Risiken begründet lag. In dieser Studie untersuchen wir die Sicherheit der Durchführung onkologischer thoraxchirurgischer Eingriffe während der COVID-19-Pandemie.

Patienten und Methoden Es wurden retrospektiv die Ergebnisse der thoraxchirurgischen Operationen bei onkologischen Patienten am Universitätsklinikum Freiburg während der 1., 2. und 3. Welle der COVID-19-Pandemie (vom 01.01. bis 30.04.2020 sowie vom 01.01. bis 30.04.2021) untersucht. Als Kontrollgruppe wurden die im gleichen Zeitraum vor der Pandemie (2018 und 2019) durchgeführten Operationen gewählt. Der primäre Endpunkt war das Auftreten postoperativer Komplikationen.

Ergebnisse 236 Operationen in der Pandemiekohorte und 227 Operationen in der Kontrollkohorte wurden in die Studie eingeschlossen. Es gab keinen Unterschied in der Inzidenzrate von postoperativen Minor-Komplikationen (16,1% vs. 18,5%, p = 0,5395) oder Major-Komplikationen (12,2% vs. 10,13%, p = 0,5563) zwischen der Pandemiekohorte und der Kontrollkohorte. Es zeigte sich kein erhöhtes Risiko für postoperative pulmonale Komplikationen in der Pandemiekohorte (Odds Ratio = 1,193, 95%-KI= 0,6515–2,203, p = 0,8232). Eine COVID-19-Infektion nach der Operation trat bei 5 Patienten der Pandemiekohorte auf (2,29%). Die postoperative Motilität innerhalb von 30 Tagen waren vergleichbar zwischen der Pandemiekohorte und der Kontrollkohorte (2 (0,85%) vs. 1 (0,44%), p > 0,9999). Es gab keine COVID-19-infektionsbedingte Mortalität.

Schlussfolgerung Die Durchführung von onkologischen thoraxchirurgischen Operationen während der COVID-19-Pandemie ist, unter Einhaltung der entsprechenden Sicherheitsmaßnahmen, sicher und weder mit einer erhöhten Komplikationsrate noch einer erhöhten Mortalität verbunden.

Abstract

Background The COVID-19 pandemic led to a major disturbance in the health care system. Many elective operations were postponed, including surgical oncology cases. Besides the need to contain hospital resources, this was also due to concerns about the safety to perform surgery during the pandemic and the impact of perioperative infections on postoperative outcomes. In this study we investigate the safety of surgery for thoracic malignancies during the COVID-19 pandemic.

Methods We retrospectively analysed the outcome of surgery for thoracic malignancies during the first, second and third waves of the COVID-19 pandemic (from 01.01. to 30.04.2020 and from 01.01. to 30.04.2021). As a control group we included the patients who received thoracic oncology surgeries during the same period in the last 2 years before the onset of the pandemic. The primary outcome was the rate of postoperative complications.

Results 236 operations were included in the pandemic group and 227 operations in the control group. There was no statistically significant difference in the rate of postoperative minor complications (16.1% vs. 18.5%, p = 0.5395) or major complications (12.2% vs. 10.13 %, p = 0.5563). The risk to develop postoperative pulmonary complications was not higher in the pandemic group (odds ratio 1.193, 95% CI 0.6515–2.203, p = 0.8232). There were 5 cases with COVID-19 infection after the operation in the pandemic group. There was no difference in the rate of postoperative mortalities (2 (0.85%) vs. 1 (0.44%), p > 0.9999) There was no COVID-19 related mortality.

Conclusion Maintaining oncologic thoracic surgery during the COVID-19 pandemic is safe, feasible and not associated with increased risks of postoperative complications or mortalities.

Publication History

Received: 18 August 2021

Accepted after revision: 23 October 2021

Article published online:
06 December 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

• Literatur

• 1 Zhu N, Zhang D, Wang W. et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020; 382: 727-733 DOI: 10.1056/NEJMoa2001017. (PMID: 31978945)
  CrossrefPubMedGoogle Scholar
• 2 Worldometer. COVID Live Update. Im Internet (Stand: 24.07.2021): https://www.worldometers.info/coronavirus/
  PubMedGoogle Scholar
• 3 Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020; 323: 1239-1242 DOI: 10.1001/jama.2020.2648. (PMID: 32091533)
  CrossrefPubMedGoogle Scholar
• 4 Stokes EK, Zambrano LD, Anderson KN. et al. Coronavirus Disease 2019 Case Surveillance – United States, January 22–May 30, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 759-765 DOI: 10.15585/mmwr.mm6924e2. (PMID: 32555134)
  CrossrefPubMedGoogle Scholar
• 5 Dai M, Liu D, Liu M. et al. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov 2020; 10: 783-791 DOI: 10.1158/2159-8290.CD-20-0422. (PMID: 32345594)
  CrossrefPubMedGoogle Scholar
• 6 CDC COVID-19 Response Team. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) – United States, February 12–March 16, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 343-346 DOI: 10.15585/mmwr.mm6912e2.
  CrossrefPubMedGoogle Scholar
• 7 Lowe KE, Zein J, Hatipoglu U. et al. Association of Smoking and Cumulative Pack-Year Exposure With COVID-19 Outcomes in the Cleveland Clinic COVID-19 Registry. JAMA Intern Med 2021; 181: 709-711 DOI: 10.1001/jamainternmed.2020.8360. (PMID: 33492361)
  CrossrefPubMedGoogle Scholar
• 8 Zhang L, Zhu F, Xie L. et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol 2020; 31: 894-901 DOI: 10.1016/j.annonc.2020.03.296. (PMID: 32224151)
  CrossrefPubMedGoogle Scholar
• 9 Nepogodiev D, Bhangu A, Glasbey JC. et al. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. Lancet 2020; 396: 27-38 DOI: 10.1016/S0140-6736(20)31182-X. (PMID: 32479829)
  CrossrefPubMedGoogle Scholar
• 10 COVIDSurg Collaborative. Elective surgery cancellations due to the COVID-19 pandemic: global predictive modelling to inform surgical recovery plans. Br J Surg 2020; 107: 1440-1449 DOI: 10.1002/bjs.11746.
  CrossrefPubMedGoogle Scholar
• 11 Diers J, Acar L, Baum P. et al. Fewer operations for cancer in Germany during the first wave of COVID-19 in 2020—a cohort study and time-series analysis. Dtsch Arztebl Int 2021; 118: 481-482 DOI: 10.3238/arztebl.m2021.0265. (PMID: 34491160)
  CrossrefPubMedGoogle Scholar
• 12 Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205-213 DOI: 10.1097/01.sla.0000133083.54934.ae.
  CrossrefPubMedGoogle Scholar
• 13 Borgstein ABJ, Brunner S, Hayami M. et al. Safety of Esophageal Cancer Surgery During the First Wave of the COVID-19 Pandemic in Europe: A Multicenter Study. Ann Surg Oncol 2021; 28: 4805-4813 DOI: 10.1245/s10434-021-09886-z. (PMID: 33830357)
  CrossrefPubMedGoogle Scholar
• 14 Smelt J, Santhirakumaran G, Vaughan P. et al. Thoracic Surgery during Coronavirus Disease 2019 (COVID-19): The Experience of a Level 1 Trauma Center. Thorac Cardiovasc Surg 2021; 69: 252-258 DOI: 10.1055/s-0040-1718938. (PMID: 33225438)
  Article in Thieme ConnectPubMedGoogle Scholar
• 15 Liang W, Guan W, Chen R. et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020; 21: 335-337 DOI: 10.1016/S1470-2045(20)30096-6. (PMID: 32066541)
  CrossrefPubMedGoogle Scholar
• 16 Shrikhande SV, Pai PS, Bhandare MS. et al. Outcomes of Elective Major Cancer Surgery During COVID 19 at Tata Memorial Centre. Ann Surg 2020; 272: e249 DOI: 10.1097/SLA.0000000000004116. (PMID: 32520743)
  CrossrefPubMedGoogle Scholar
• 17 Seitlinger J, Wollbrett C, Mazzella A. et al. Safety and feasibility of thoracic malignancy surgery during the COVID-19 pandemic. Ann Thorac Surg 2020; DOI: 10.1016/j.athoracsur.2020.12.001.
  CrossrefPubMedGoogle Scholar
• 18 Khorana AA, Tullio K, Elson P. et al. Time to initial cancer treatment in the United States and association with survival over time: An observational study. PLoS One 2019; 14: e0213209 DOI: 10.1371/journal.pone.0213209. (PMID: 30822350)
  CrossrefPubMedGoogle Scholar
• 19 Bertolaccini L, Sedda G, Spaggiari L. Paying Another Tribute to the COVID-19 Pandemic: The Decrease of Early Lung Cancers. Ann Thorac Surg 2021; 111: 745-746 DOI: 10.1016/j.athoracsur.2020.11.013. (PMID: 33279552)
  CrossrefPubMedGoogle Scholar
• 20 Heiden BT, Eaton jr. DB, Engelhardt KE. et al. Analysis of Delayed Surgical Treatment and Oncologic Outcomes in Clinical Stage I Non-Small Cell Lung Cancer. JAMA Netw Open 2021; 4: e2111613 DOI: 10.1001/jamanetworkopen.2021.11613. (PMID: 34042991)
  CrossrefPubMedGoogle Scholar